Cord Blood America, Inc. (OTCBB: CBAI) is focused on saving lives through umbilical cord blood stem cell preservation. Matthew Schissler, the company’s CEO, recently took part in a StoxRox.com interview to discuss achievements and the future outlook for the company. Schissler said the focus of the Cord Blood America is to significantly reduce its debt and position itself to operate off its own cash flow.
According to Schiller, the company is outpacing every blood company in the industry, executing the company’s promise to shareholders that it would grow rapidly in 2006 and 2007. “We have grown faster than any other cord blood company in the industry, which took a lot of funding. Our valuation is much lower than our competitors and we look for improvement as we decrease this debt level,” Schissler stated in the interview.
Cord Blood America reported a 500% increase in its customer base in 2007, growing from 3,000 to 18,000. For those thousands of customers, the company facilitates umbilical cord blood stem cell preservation, collected in a safe and non-invasive process. The stem cells are then stored, for a fee, in case of an emergency or ailment such as cancer, leukemia or immune disorders. If such ailments afflict a member of the family, cord blood stem cells are at hand for treatment.
Let us hear your thoughts: Cord Blood America Inc. Message Board